Pharmaceutical companies in jordan export drugs to USA
1,213 views
http://phrmacistsworld.com
Pharmaceutical companies in jordan now export more than 120M $ every year to USA , Jordan now is the highest export sour...
Pharmaceutical companies in jordan now export more than 120M $ every year to USA , Jordan now is the highest export sour...
http://phrmacistsworld.com
Pharmaceutical companies in jordan now export more than 120M $ every year to USA , Jordan now is the highest export source for drugs in the Middle East
1:38 Pharmacists and Patient Counseling in Diabetic Patients
7,417 views
www.PharmacistsWorld.com
Pharmacists patient education in diabetes monitoring , pharmacist has big role , Pharmacy,
diabetes, education, in the pha...
Pharmacists patient education in diabetes monitoring , pharmacist has big role , Pharmacy,
diabetes, education, in the pha...
Jordan's pharmaceutical industry abides by the new TRIPS-consistent patent law. In addition, with the signing of the U.S.-Jordan FTA, Jordan committed to even stronger enforcement of intellectual property rights, particularly in the pharmaceutical sector. According to Economic and Trade Officer Greg Lawless at the U.S. Embassy in Amman, intellectual property rights enforcement has improved in Jordan. "Effective enforcement mechanisms and legal procedures, still not completed, are undergoing further refinement," he said. Although significant challenges remain, Jordan's enforcement action against audio/video and software piracy is growing in quantity and improving its capability to target problem areas, he added.
According to the Pharmaceutical Manufacturers Association of America (PhRMA), the U.S.-Jordan FTA has made Jordan's market more appealing for pharmaceutical research and development, as well as for sales and licensing agreements. The benefits of the U.S.-Jordan FTA for industry include expanded data protection, elimination of exclusions from patentability for biotechnology inventions, and limitations on compulsory licensing.
In October 2001, PhRMA established an office in Amman to serve the Middle East and North Africa region. It was PhRMA's first presence in the region. Jordan's commitment to free trade and high-standard business practices were decisive factors in the decision, according to Susan Finston, PhRMA's associate vice president. "Jordan was the place where in less than 45 business days we could open an office, get credentials, and have all of the infrastructure and the legal permits that we needed for business," she said.
Many PhRMA members have established or expanded their commercial activities in Amman, including American Home Products, Astra-Zeneca, Sanofi-Aventis, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen-Cilag, Merck Sharp & Dohme, Novartis, Organon, Roche, Pfizer, and Schering-Plough.
Several PhRMA members are conducting clinical trials and entering into co-marketing and/or licensing agreements with Jordanian companies. According to the International Intellectual Property Institute (IIPI), a nonprofit economic development organization and think tank based in Washington, D.C., Bristol-Myers Squibb initiated a three-year, 5,000-patient cardiovascular risk factor study in Jordan in 2001. Moreover, PhRMA reports that, in 2004 alone, its member companies carried out 19 clinical trials in Jordan for conditions such as cancer, osteoporosis, diabetes, and cardiovascular disease.
HIKMA
RAM PHARM
According to the Pharmaceutical Manufacturers Association of America (PhRMA), the U.S.-Jordan FTA has made Jordan's market more appealing for pharmaceutical research and development, as well as for sales and licensing agreements. The benefits of the U.S.-Jordan FTA for industry include expanded data protection, elimination of exclusions from patentability for biotechnology inventions, and limitations on compulsory licensing.
In October 2001, PhRMA established an office in Amman to serve the Middle East and North Africa region. It was PhRMA's first presence in the region. Jordan's commitment to free trade and high-standard business practices were decisive factors in the decision, according to Susan Finston, PhRMA's associate vice president. "Jordan was the place where in less than 45 business days we could open an office, get credentials, and have all of the infrastructure and the legal permits that we needed for business," she said.
Many PhRMA members have established or expanded their commercial activities in Amman, including American Home Products, Astra-Zeneca, Sanofi-Aventis, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen-Cilag, Merck Sharp & Dohme, Novartis, Organon, Roche, Pfizer, and Schering-Plough.
Several PhRMA members are conducting clinical trials and entering into co-marketing and/or licensing agreements with Jordanian companies. According to the International Intellectual Property Institute (IIPI), a nonprofit economic development organization and think tank based in Washington, D.C., Bristol-Myers Squibb initiated a three-year, 5,000-patient cardiovascular risk factor study in Jordan in 2001. Moreover, PhRMA reports that, in 2004 alone, its member companies carried out 19 clinical trials in Jordan for conditions such as cancer, osteoporosis, diabetes, and cardiovascular disease.
Jordan's Hikma is the first Arab pharmaceutical company to export one of its products to the U.S. market
Read more: http://iipdigital.usembassy.gov/st/english/publication/2008/04/20080429215159myleen0.5241358.html#ixzz29HlC41ie
Read more: http://iipdigital.usembassy.gov/st/english/publication/2008/04/20080429215159myleen0.5241358.html#ixzz29HlC41ie
HIKMA
RAM PHARM
No comments:
Post a Comment